Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis

Rheumatology

Volumn 49, Issue 11, 2010, Pages 2135-2139

  Ueda Hayakawa, Ikuko ^a,b   Hasegawa, Minoru ^a   Kumada, Sayako ^a   Tanaka, Chihiro ^a   Komura, Kazuhiro ^a   Hamaguchi, Yasuhito ^a   Takehara, Kazuhiko ^a   Fujimoto, Manabu ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Anti cyclic citrullinated peptide antibody; Rheumatoid arthritis; Systemic sclerosis

Indexed keywords

ANTICYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PEPTIDE ANTIBODY; RHEUMATOID FACTOR; STROMELYSIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTHRITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS;

AGED; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY;

EID: 78649371099     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq205     Document Type: Article

References (17)

1. Schellekens GA, Visser H, de Jong BA et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
2. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
3. LeRoy EC, Krieg T, Black C et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
4. Hayakawa I, Hasegawa M, Matsushita T et al. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis. Rheumatology 2005;44: 873-8.
5. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
6. Clements PJ, Lachenbruch PA, Seibold JR et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
7. Santiago M, Baron M, Miyachi K et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 2008; 27:77-83.
8. Avouac J, Guerini H, Wipff J et al. Radiological hand involvement in systemic sclerosis. Ann Rheum Dis 2006; 65:1088-92.
9. Tuffanelli DL, Winkelmann RK. Systemic scleroderma, a clinical study of 727 cases. Arch Dermatol 1961;84:359-71.
10. Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N, Tamaki K. Clinical features of patients with systemic sclerosis accompanied by rheumatoid arthritis. Clin Exp Rheumatol 2003;21:91-4.
11. Szucs G, Szekanecz Z, Zilahi E et al. Systemic sclerosis-rheumatoid arthritis overlap syndrome: a unique combination of features suggests a distinct genetic, serological and clinical entity. Rheumatology 2007;46:989-93.
12. Mimura Y, Ihn H, Jinnin M et al. Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis. Br J Dermatol 2004;151:803-8.
13. Generini S, Steiner G, Miniati I et al. Anti-hnRNP and other autoantibodies in systemic sclerosis with joint involvement. Rheumatology 2009;48:920-5.
14. Okada Y, Nagase H, Harris ED, Jr. Matrix metalloproteinases 1, 2, and 3 from rheumatoid synovial cells are sufficient to destroy joints. J Rheumatol 1987;14 Spec No: 41-2.
15. Manicourt DH, Fujimoto N, Obata K, Thonar EJ. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum 1995;38:1031-9.
16. Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 1995;38:969-75.
17. Jinnin M, Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K. Serum matrix metalloproteinase-3 in systemic sclerosis. Arch Dermatol Res 2004;296:25-9.